1 / 33

Rubella and Rubella Vaccine

Rubella and Rubella Vaccine. Epidemiology and Prevention of Vaccine-Preventable Diseases National Immunization Program Centers for Disease Control and Prevention. Dr Esteghamati EPI Manager. Rubella. From Latin meaning "little red"

eldon
Télécharger la présentation

Rubella and Rubella Vaccine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rubella and Rubella Vaccine Epidemiology and Prevention of Vaccine-Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Dr Esteghamati EPI Manager

  2. Rubella • From Latin meaning "little red" • Discovered in 18th century - thought to be variant of measles • First described as distinct clinical entity in German literature • Congenital rubella syndrome described by Gregg in 1941

  3. Rubella Virus • Togavirus • RNA virus • One antigenic type • Rapidly inactivated by chemical agents, low pH, heat and ultraviolet light

  4. Rubella Pathogenesis • Respiratory transmission of virus • Replication in nasopharynx and regional lymph nodes • Viremia 5-7 days after exposure with spread to tissues • Placenta and fetus infected during viremia

  5. Rubella Clinical Features • Incubation period 14 days (range 12-23 days) • Prodrome of low grade fever • Lymphadenopathy in second week • Maculopapular rash 14-17 days after exposure

  6. Rubella Complications rare up to 70% 1/3000 cases 1/6,000 cases rare rare Arthralgia or arthritis children adult female Thrombocytopenic purpura Encephalitis Neuritis Orchitis

  7. Congenital Rubella Syndrome • Infection may affect all organs • May lead to fetal death or premature delivery • Severity of damage to fetus depends on gestational age • Up to 85% of infants affected if infected during first trimester

  8. Congenital Rubella Syndrome (CRS)

  9. Congenital Rubella Syndrome • Deafness • Cataracts • Heart defects • Microcephaly • Mental retardation • Bone alterations • Liver and spleen damage

  10. CRS case definitions (1) Suspected CRS:A child <1 year with • maternal history of rubella in pregnancy and/or • heart disease, or deafness, or eye signs: white pupil (cataract); diminished vision; pendular eye movement (nystagmus); squint; smaller eye ball (micropthalmos);larger eye ball (congenital glaucoma)

  11. CRS case definitions (2) Clinically confirmed CRS:A child <1 year with two complications in group (a) or one from (a) and one from (b) (a) cataract(s), congenital glaucoma, congenital heart disease, loss of hearing, pigmentary retinopathy (b) purpura, splenomegaly, microcephaly, mental retardation, meningoencephalitis, radiolucent bone disease, jaundice with onset within 24 hours after birth.

  12. CRS case definitions (3) Laboratory-confirmed CRS: An infant with a positive blood test for rubella-specific IgM and clinically-confirmed CRS. Congenital rubella infection (CRI): An infant with a positive blood test for rubella-specific IgM who does not have clinically-confirmed CRS.

  13. TOP PRIORITY: Use rubella vaccine to prevent CRS • To prevent CRS introduce rubella vaccine for women of childbearing age • Define age of target group • consider local fertility rates • Where to offer vaccine • postpartum and family planning • mass campaigns (Cuba, Malaysia)

  14. Epidemic Rubella – United States, 1964-1965 • 12.5 million rubella cases • 2,000 encephalitis cases • 11,250 abortions (surgical/spontaneous) • 2,100 neonatal deaths • 20,000 CRS cases • Deaf - 11,600 • Blind - 3,580 • Mentally retarded - 1,800

  15. Rubella Laboratory Diagnosis • Isolation of rubella virus from clinical specimen (e.g., nasopharynx, urine) • Significant rise in rubella IgG by any standard serologic assay (e.g., enzyme immunoassay) • Positive serologic test for rubella IgM antibody

  16. Rubella Epidemiology • Reservoir Human • Transmission Respiratory Subclinical cases may transmit • Temporal pattern Peak in late winter and spring • Communicability 7 days before to 5-7 days after rash onset Infants with CRS may shed virus for a year or more

  17. Rubella - United States, 1966-2002

  18. Rubella - United States, 1980-2002

  19. Rubella - United States, 1980-2002Age Distribution of Reported Cases 15-39 yrs <5 yrs 5-14 yrs >40 yrs

  20. Rubella and CRS in the United States • Most reported rubella in the U.S. since the mid-1990s has occurred among foreign-born Hispanic adults • Rubella outbreaks have occurred in workplaces where most employees are foreign-born • Majority of CRS since 1997 occurred in children of unvaccinated women born to Hispanic women, most born in Latin America

  21. Rubella Case Definition • Acute onset of generalized maculopapular rash, and • Temperature of >37.2 C (>99 F), if measured, and • Arthralgia or arthritis, or lymph-adenopathy, or conjunctivitis

  22. Rubella Outbreak Control Guidelines • Laboratory diagnosis of rubella and CRS • Step-by-step guidelines on evaluation and management of outbreak • Rubella prevention and control among women of childbearing age • Rubella and CRS surveillance MMWR 2001;50(RR-12)

  23. Trade Name Cendevax Rubelogen Meruvax Meruvax II Licensure 1969 1969 1969 1979 Vaccine GMK-3:RK53 HPV-77:DK12 HPV-77:DE5 RA 27/3* Rubella Vaccine *Only vaccine currently licensed in U.S.

  24. Rubella Vaccine • Composition Live virus (RA 27/3 strain) • Efficacy 95% (Range, 90%-97%) • Duration ofImmunity Lifelong • Schedule >1 Dose • Should be administered with measles and mumps as MMR

  25. Rubella Vaccine (MMR) Indications • All infants >12 months of age • Susceptible adolescents and adults without documented evidence of rubella immunity • Emphasis on non-pregnant women of childbearing age, particularly those born outside the U.S.

  26. Rubella Immunity • Documentation of one dose of rubella-containing vaccine on or after the first birthday • Serologic evidence of immunity • Birth before 1957 (except women of childbearing age)

  27. Rubella Immunity • Birth before 1957 is not acceptable evidence of rubella immunity for women who might become pregnant • Only serology or documented vaccination should be accepted

  28. MMR Adverse Reactions • Fever 5%-15% • Rash 5% • Joint symptoms 25% • Thrombocytopenia <1/30,000 doses • Parotitis rare • Deafness rare • Encephalopathy <1/1,000,000 doses

  29. Rubella Vaccine Arthropathy • Acute joint symptoms in about 25% of susceptable adult women • Frank arthritis occurs in about 10% • Rare reports of chronic or persistent symptoms • Population-based studies have not confirmed association

  30. MMR VaccineContraindications and Precautions • Severe allergic reaction to vaccine component or following prior dose • Pregnancy • Immunosuppression • Moderate or severe acute illness • Recent blood product

  31. Vaccination of Women of Childbearing Age • Ask if pregnant or likely to become so in next 4 weeks • Exclude those who say "yes" • For others • Explain theoretical risks • Vaccinate

  32. Vaccination in Pregnancy Study 1971-1989 • 321 women vaccinated • 324 live births • No observed CRS • 95% confidence limits 0%-1.2%

  33. Rubella VaccineRecommendations for Increasing Coverage • Continued routine vaccination of children at age >12 months with vaccination required for school entry • Screen and vaccinate susceptible persons • healthcare workers • college entry • prenatal with postpartum vaccination • other healthcare visits • workplace

More Related